MediciNova completes patient enrollment in MN-001-NATG-202 trial

MediciNova (MNOV) announces the completion of patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 for the treatment of hypertriglyceridemia and non-alcoholic fatty liver disease due to Type 2 diabetes. Patient recruitment is closed. The MN-001-NATG-202 study is a multi-center, randomized, double-blind, placebo-controlled trial to evaluate MN-001. Patients are randomized 1:1 to receive either 500 mg/day of MN-001 or placebo for 24 weeks. The co-primary endpoints are change from baseline in liver fat content measured by controlled attenuation parameter score at Week 24, and change from baseline in fasting serum triglycerides at Week 24. Secondary endpoints include safety and tolerability and changes in lipid profile. Top-line data are expected by the summer of 2026